# Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)

> **NCT00475215** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 86 (actual)

## Conditions studied

- Anesthesia, General

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Rocuronium

## Key facts

- **NCT ID:** NCT00475215
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10-27
- **Primary completion:** 2006-08-21
- **Final completion:** 2006-09-09
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2019-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00475215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00475215, "Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00475215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*